Pharmala Biotech Holdings Inc. (CSE:MDMA)
0.1600
-0.0050 (-3.03%)
May 21, 2026, 3:59 PM EST
Pharmala Biotech Holdings Revenue
Pharmala Biotech Holdings had revenue of 280.58K CAD in the quarter ending February 28, 2026, with 92.63% growth. This brings the company's revenue in the last twelve months to 889.57K, up 106.79% year-over-year. In the fiscal year ending August 31, 2025, Pharmala Biotech Holdings had annual revenue of 605.50K, down -41.51%.
Revenue (ttm)
889.57K
Revenue Growth
+106.79%
P/S Ratio
20.20
Revenue / Employee
n/a
Employees
n/a
Market Cap
17.97M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2025 | 605.50K | -429.80K | -41.51% |
| Aug 31, 2024 | 1.04M | 503.29K | 94.60% |
| Aug 31, 2023 | 532.00K | 453.93K | 581.44% |
| Aug 31, 2022 | 78.07K | - | - |
| Aug 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Microbix Biosystems | 14.81M |
| Devonian Health Group | 10.18M |
| Rapid Dose Therapeutics | 2.78M |
| Glow Lifetech | 2.05M |
| Britannia Life Sciences | 157.68K |
Pharmala Biotech Holdings News
- 1 day ago - PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million - GlobeNewsWire
- 8 days ago - PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01 - GlobeNewsWire
- 24 days ago - PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01 - GlobeNewsWire
- 4 weeks ago - PharmAla Issues Q2 Financial Statements and Grants Options - GlobeNewsWire
- 4 weeks ago - Pharmala Biotech Holdings Earnings release: Q2 2026 - Filings
- 4 weeks ago - Pharmala Biotech Holdings Registration statement: Q2 2026 - Filings
- 4 weeks ago - Pharmala Biotech Holdings Registration statement: Q2 2026 - Filings
- 4 weeks ago - PharmAla positioned to supply U.S. expanded access pathway for MDMA - TheFly